Last reviewed · How we verify
SP-2577 Seclidemstat — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SP-2577 Seclidemstat (SP-2577 Seclidemstat) — Salarius Pharmaceuticals, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SP-2577 Seclidemstat TARGET | SP-2577 Seclidemstat | Salarius Pharmaceuticals, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SP-2577 Seclidemstat CI watch — RSS
- SP-2577 Seclidemstat CI watch — Atom
- SP-2577 Seclidemstat CI watch — JSON
- SP-2577 Seclidemstat alone — RSS
Cite this brief
Drug Landscape (2026). SP-2577 Seclidemstat — Competitive Intelligence Brief. https://druglandscape.com/ci/sp-2577-seclidemstat. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing